LAWRENCEVILLE, N.J., Oct. 7, 2014 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN) is saddened to announce the passing of Max E. Link, Ph.D., a Director and the Chairman of the Board of Directors of the Company.  Dr. Link passed away unexpectedly at the age of 74.

Michael H. Tardugno, President and Chief Executive Officer of Celsion, stated, "Max was a pillar in the pharmaceutical industry – a visionary who believed in the transformative power of science to positively impact human health.  His contributions over the course of his distinguished career will leave a lasting legacy, and all of us at Celsion are indebted to him for his leadership, support and friendship. We are deeply saddened and mourn his loss."

Dr. Link served on Celsion's Board of Directors since 1997 and as Chairman of the Board since 2001.  The Board of Directors has begun the process to identify qualified candidates to fill the vacancy on the Board. 

During Dr. Link's distinguished career, he served in numerous positions with Sandoz Pharmaceuticals (now part of Novartis), culminating in his appointment as Chairman of its Board of Directors in 1992. From 1993 to 1994, Dr. Link served as Chief Executive Officer of Corange, Ltd., the parent company of Boehringer Mannheim Therapeutics, Boehringer Mannheim Diagnostics and DePuy Orthopedics.  From 2001 to 2003, Dr. Link served as Chairman and Chief Executive Officer of Centerpulse AG, a medical implant company.  Dr. Link also served on the Board of Directors of numerous development stage companies within the biopharmaceutical and medical device fields, both private and public companies. 

About Celsion Corporation

Celsion is a fully-integrated oncology company focused on developing a portfolio of innovative cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies. The Company's lead program is ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently in Phase III development for the treatment of primary liver cancer. The pipeline also includes EGEN-001, a DNA-based immunotherapy for the localized treatment of ovarian and brain cancers.  Celsion has three platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies, including TheraPlas™, TheraSilence™ and RAST ™.  For more information on Celsion, visit our website: http://www.celsion.com.

Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995.  Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials; the uncertainties of and difficulties in analyzing interim clinical data, particularly in small subgroups that are not statistically significant; FDA and regulatory uncertainties and risks; the significant expense, time, and risk of failure of conducting clinical trials; the need for Celsion to evaluate its future development plans; possible acquisitions or licenses of other technologies, assets or businesses or the possible failure to make such acquisitions or licenses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Celsion's periodic reports and prospectuses filed with the Securities and Exchange Commission.  Celsion assumes no obligation to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.

Celsion Investor Contact
Jeffrey W. Church
Sr. Vice President and CFO
609-482-2455
jchurch@celsion.com

SOURCE Celsion Corporation

Copyright 2014 PR Newswire

Celsion (NASDAQ:CLSN)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Celsion Charts.
Celsion (NASDAQ:CLSN)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Celsion Charts.